There’s been considerable hat-changing in FDA leadership during the past week, as the White House looks to bring in credible experts for its Operation Warp Speed initiative to advance therapies and vaccines to combat the coronavirus pandemic. This prompted major leadership changes at FDA, with Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), stepping down temporarily from that role in order to head up the administration’s efforts to identify and accelerate development of promising treatments and preventives pending development of a new vaccine against COVID-19.
